Welldoc Powers Lilly Health™ App with AI-Enhanced Cardiometabolic Digital Health Solutions

Welldoc® has partnered with Eli Lilly and Company to provide the technology behind the newly launched Lilly Health™ app, aimed at enhancing patient experiences for users of Lilly’s incretin-based therapies, such as Zepbound® and Mounjaro®. This app will support individuals dealing with obesity, type 2 diabetes, and obstructive sleep apnea linked to obesity. Designed for adults 18 and older, the app integrates educational resources and offers tools for managing cardiometabolic health, including medication tracking, reminders, and connectivity with health devices. It is built on Welldoc’s established digital platform, providing extensive resources for nutrition, exercise, and health data insights. While it aims to optimize health management in collaboration with healthcare providers, it does not replace professional medical advice. Kevin McRaith, President and CEO of Welldoc, expressed pride in this collaboration, highlighting the platform’s ability to deliver personalized support for complex health conditions.

Source link